Your session is about to expire
Sglt2 vs Sglt1
Introduction
For patients with type 2 diabetes mellitus (T2DM), certain drugs target specific transport proteins in the kidneys, called SGLTs or sodium-glucose co-transporters. These can help lower blood sugar levels and manage symptoms of T2DM. Drugs targeting SGLT2 and SGLT1 are two such categories prescribed for this condition. They each impact different transport proteins but both have a role in regulating glucose levels in patients with T2DM.
SGLT2 inhibitors primarily prevent reabsorption of glucose by the kidneys, leading to excretion of excess glucose through urine, thereby reducing blood sugar levels. On the other hand, SGLT1 inhibitors work mainly on inhibiting glucose absorption in the intestines as well as minimal inhibition in renal proximal tubules which results not only lowering post-meal blood sugar spikes but also providing cardiovascular benefits because they slow down how quickly carbohydrates are absorbed into circulation.
Sglt2 vs Sglt1 Side By Side
| Attribute | Jardiance | Zynquista |
|---|---|---|
| Brand Name | Jardiance | Zynquista |
| Contraindications | Severe renal impairment, end-stage renal disease (ESRD), dialysis patients, known hypersensitivity reactions | Severe renal impairment, end-stage renal disease (ESRD), dialysis patients, known hypersensitivity reactions |
| Cost | $600 for a 30-tablet supply | Upwards from $1200 for a month's supply |
| Generic Name | Empagliflozin | Sotagliflozin |
| Most Serious Side Effect | Diabetic Ketoacidosis | Diabetic Ketoacidosis, Gastrointestinal issues |
| Severe Drug Interactions | Certain diuretics and other antidiabetic drugs | Certain diuretics and other antidiabetic drugs |
| Typical Dose | 100-300 mg/day | 100-200 mg/day, up to 450 mg/day |
What is Sglt2?
Sodium-glucose cotransporter-2 (SGLT2) inhibitors represent a significant advancement in diabetes management, akin to the impact of Fluoxetine on antidepressant drug development. SGLT2 proteins are primarily found in the kidneys and play a role in reabsorbing glucose back into the blood stream from primary urine. By inhibiting these transporters, SGLT2 inhibitors allow excess glucose to be excreted through urine, effectively lowering blood sugar levels without causing insulin release.
On the other hand, Sodium-glucose cotransporter-1 (SGLT1) is mainly located in the intestines where it aids in glucose absorption during digestion. Inhibitors of this transporter may have additional benefits beyond improving glycemic control but could also lead to gastrointestinal side effects due to their site of action.
Despite functioning similarly by affecting how our body handles glucose, SGLT2 has been more widely used clinically for managing diabetes due its selective location and function resulting in fewer adverse events compared with potential effects of interfering with intestinal SGLT1 transporter.
What conditions is Sglt2 approved to treat?
SGLT2 inhibitors have been approved for the treatment of several conditions related to metabolic disorders:
- Type 2 Diabetes, by improving glycemic control through enhancing urinary glucose excretion
- Heart failure with reduced ejection fraction, in combination with other therapies
- Chronic kidney disease (CKD), in diabetic patients.
On the other hand, SGLT1 inhibitors are still under investigation and not yet approved for clinical use. However, early research suggests potential benefits in treating type 2 diabetes and obesity.
How does Sglt2 help with these illnesses?
SGLT2 inhibitors work to manage diabetes by reducing the amount of glucose reabsorbed in the kidneys, thus allowing for higher amounts of glucose to be excreted through urine. This process takes place in the proximal tubule of our kidneys where SGLTs (sodium-glucose transport proteins) are located. These proteins play a crucial role in maintaining blood glucose levels, and variations can impact insulin sensitivity, energy regulation, hunger and body weight among other things.
In individuals with type 2 diabetes, there is an increased reabsorption of glucose due to hyperactivation of these SGLT proteins which contributes to high blood sugar levels. Therefore, by inhibiting SGLT2 specifically (which accounts for 90% of renal glucose reabsorption), drugs like Empagliflozin or Dapagliflozin help reduce blood sugar levels significantly.
On the other hand, though similar in function and location on the same organ - kidney's proximal tubules; SGLT1 differs from its counterpart as it plays a secondary role absorbing remaining 10% generally after SGLT2 has done its part but most importantly aids absorption from dietary carbohydrates within intestines too. Hence inhibition here would have different therapeutic implications.
What is Sglt1?
SGLT1, or Sodium-glucose co-transporter 1, is a protein that in humans is encoded by the SLC5A1 gene. It facilitates the transport of glucose and galactose across the brush border membrane of epithelial cells in the small intestine and kidney. This transporter plays a crucial role in glucose absorption from our diet.
Unlike SGLT2 inhibitors which primarily work on blocking glucose reabsorption in kidneys, potential drugs targeting SGLT1 could limit how much dietary glucose can be absorbed into your bloodstream through your intestines.
It's important to note that while both play significant roles in managing blood sugar levels, their functions are distinctively different. The actions of SGLT1 affect more directly dietary intake related responses whereas those of SGLT2 have implications for renal function and overall glycemic control.
What conditions is Sglt1 approved to treat?
The SGLT1 (Sodium-glucose co-transporter 1) is an integral membrane protein that exists in many tissues of the body but is predominantly found in the small intestines and kidneys. It plays a crucial role in:
- The absorption of glucose and galactose from food intake within the gut
- Reabsorption of filtered glucose within the kidney
Therefore, it greatly impacts both our digestive function and renal physiology.
How does Sglt1 help with these illnesses?
SGLT1, or Sodium-Glucose Transport Protein 1, is a protein that plays a crucial role in glucose and galactose absorption in the small intestine. It also facilitates glucose reabsorption in the kidneys. This protein works by increasing the levels of glucose available to cells for energy production, thereby aiding many bodily functions such as memory recall and focus. Its action on other nutrients may also play roles in various bodily processes like wound healing and maintaining energy levels during stress conditions. Because SGLT1 has more affinity towards sugar molecules than its counterpart SGLT2 (which mainly operates in kidney), it's often targeted when there are issues with intestinal sugar absorption or metabolism-related diseases such as diabetes. So while medications inhibiting SGLT2 have been used widely for managing blood sugar levels among diabetics, drugs targeting SGLT1 can be considered when these typical methods fail to deliver desired results.
How effective are both Sglt2 and Sglt1?
Both SGLT2 (sodium-glucose co-transporter 2) and SGLT1 (sodium-glucose co-transporter 1) are integral in glucose homeostasis, but they play distinct roles due to their varied tissue distribution and affinity for glucose. While both were discovered around the same time - in the late 20th century - understanding of their function has evolved over time.
SGLT2 is primarily located in the kidney where it's responsible for about 90% of renal glucose reabsorption. Inhibition of SGLT2 leads to increased excretion of glucose in urine, making SGLT2 inhibitors a viable treatment option for type-2 diabetes mellitus.
In contrast, SGLT1 resides mostly in the small intestine where it absorbs dietary sugars. It also plays a role in renal absorption albeit much less than its counterpart; only about 10%. Therefore, inhibiting this transporter can reduce postprandial hyperglycemia by delaying intestinal sugar absorption.
A head-to-head study comparing these two transporters directly hasn't been conducted yet as they serve different physiological functions. However, dual inhibitors targeting both transporters have shown potential benefits but with an increased risk of side effects like diarrhea due to excess sugar remaining unabsorbed by intestines.
Researchers continue to explore the unique properties and potentials of each transporter including studies on using selective inhibition or combined therapy involving both SGLTs which could offer a broader therapeutic index especially for those patients whose condition failed to improve significantly with first-line treatments like metformin.
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Sglt2 typically prescribed?
SGLT2 inhibitors are typically prescribed in doses ranging from 100-300 mg/day, depending on the patient's tolerance and response. They have been shown to be effective for managing blood glucose levels in adults with type 2 diabetes. On the other hand, SGLT1 inhibitors are currently primarily used in research settings, with dosage varying widely based on the specific study or experimental design. In all cases of medication use, it is important to start at a lower dose and monitor responses before increasing dosage if necessary. The maximum safe daily dose will depend largely on individual factors such as age, weight, kidney function and overall health status.
At what dose is Sglt1 typically prescribed?
SGLT1 inhibitors are generally initiated at a dosage of 100-200 mg/day. If necessary, doses can then be increased to 300 mg/day, divided into two separate intakes, spaced approximately 8 hours apart. In some cases where the response to treatment is inadequate after several weeks at the initial dose, the daily dose may be further escalated up to a maximum of 450 mg/day. This would typically involve dividing it into three doses of 150 mg each and spacing them about 6 hours apart. As with all medications however, patients should always follow their healthcare provider's instructions regarding dosing adjustments based on individual needs and responses.
What are the most common side effects for Sglt2?
When comparing SGLT2 inhibitors to SGLT1 inhibitors, it's important to note that they target different areas and have distinct side effects.
SGLT2 inhibitors are commonly used in the treatment of type 2 diabetes and may result in the following side effects:
- Urinary tract infections
- Fungal infections (such as thrush)
- Increased urination
- Thirst
- Constipation or diarrhea
- Fatigue, weakness
- Nausea
On the other hand, there is less clinical data on SGLT1 inhibitors as they're still under extensive research for their potential use. However, some proposed side effects might include:
- Gastrointestinal issues such as bloating, gas, abdominal discomfort
Are there any potential serious side effects for Sglt2?
While SGLT1 and SGLT2 inhibitors aren't typically associated with mental health changes, it's important to note possible side effects which can differ between the two:
- Signs of a urinary tract infection (UTI) or yeast infection: These are more common in patients taking SGLT2 inhibitors, due to the mechanism of these medications increasing glucose excretion through urine. Symptoms include frequent urination, burning sensation during urination, strong-smelling urine or vaginal discharge.
- Dehydration symptoms: Both types of medication may increase the risk for dehydration if not properly managed. This could result in dizziness, fainting spells, rapid heartbeat and low blood pressure.
- Hypoglycemia - While both classes can potentially cause low blood sugar levels when combined with other diabetes medications like insulin or sulfonylureas; this is generally less common with SGLT2 inhibitors than with SGLT1 inhibitors.
- Diabetic Ketoacidosis (DKA): A serious complication characterized by nausea, vomiting, abdominal pain and confusion. Although rare it has been reported slightly more frequently in patients on SLGT2-inhibitors.
If you experience any of these symptoms while using either an SGLT1 or an SGLT2 inhibitor, contact your healthcare provider immediately.
What are the most common side effects for Sglt1?
It's important to note that SGLT1 and SGLT2 are not actual medications, but rather types of proteins called Sodium-Glucose Cotransporter-1 and 2. They play different roles in the body's regulation of glucose absorption. While SGLT2 inhibitors have been developed as a class of drugs for managing diabetes, most side effects associated with them would not apply to SGLT1.
Inhibition or dysfunction of the SGLT1 protein could potentially lead to:
- Gastrointestinal issues such as diarrhea, bloating, gas, stomach cramps
- Dehydration due to frequent bowel movement
- Nutrient malabsorption leading to weight loss
- Electrolyte imbalance causing symptoms like fatigue, muscle weakness or spasms
Again, these effects would result from a malfunctioning or inhibited SGLT1 protein itself and aren't associated with any specific drug treatment. Always consult your healthcare provider if you're experiencing health concerns.
Are there any potential serious side effects for Sglt1?
SGLT1 (sodium-glucose co-transporter 1) is a protein that aids in glucose absorption, and while it does not directly cause side effects like pharmaceutical drugs might, certain physiological changes related to its function could lead to symptoms or conditions such as:
- Signs of dehydration: dizziness, feeling faint, rapid heartbeat or pulse
- Gastrointestinal issues: stomach cramps, diarrhea
- Hypoglycemia due to increased insulin sensitivity and decreased blood sugar levels - this may present with symptoms such as continuous hunger, confusion, irritability
- Salt imbalance leading to muscle spasms or weakness
It's important to clarify here that SGLT1 is not a medication but rather an integral part of the body's mechanism for regulating sugar levels. If you are experiencing any unusual health problems or concerns about your well-being linked with these functions in your body after starting new dietary habits or medications targeting this area specifically (like SGLT2 inhibitors), please consult with your doctor immediately.
Contraindications for Sglt2 and Sglt1?
Both SGLT2 and SGLT1 inhibitors, common types of diabetes medications, may exacerbate symptoms of metabolic health issues in some individuals. If you notice your blood sugar levels fluctuating abnormally or if there are any changes to your kidney function or urinary habits, please consult with a healthcare provider immediately.
Neither an SGLT2 nor an SGLT1 inhibitor should be taken if you have been using certain kinds of diuretics or other antidiabetic drugs. Always inform your physician about all the medications that you are taking; these diuretics and antidiabetic drugs will require a period of adjustment before initiating therapy with either an SGLT2 or SGLT1 inhibitor to prevent potential harmful interactions.
It's crucial to note that people with severe renal impairment, end-stage renal disease (ESRD), dialysis patients, or those who have known hypersensitivity reactions to these classes of medicines should not use them. In addition, they must also be used cautiously in elderly patients as they might increase the risk for volume depletion and hypotension.
How much do Sglt2 and Sglt1 cost?
SGLT1 and SGLT2 are not medications, but types of proteins (sodium-glucose transport proteins) involved in glucose regulation within the body. They serve as targets for certain classes of drugs used to treat type 2 diabetes mellitus.
SGLT2 inhibitors such as Invokana (canagliflozin), Farxiga (dapagliflozin), or Jardiance (empagliflozin) are commonly used. For example:
- The price for a 30-tablet supply of Jardiance (10 mg) is approximately $600, coming out to around $20 per day.
- Meanwhile, a similar quantity/dosage of Invokana costs about $580, averaging nearly $19 per day.
As yet, there aren't any commercially available SGLT1 inhibitors on their own; however dual SGLT1/SGLT2 inhibitor Zynquista(sotagliflozin) has been approved in Europe:
- A month's supply can cost upwards from $1200 which works out to be about $40/day depending on your dose.
Please remember that these prices may vary based on location and insurance coverage. Also note that while cost is an important factor when considering medication options, it should not be the primary determinant - efficacy and safety profile must also be taken into account. As always consult with your healthcare provider for best treatment plan.
Popularity of Sglt2 and Sglt1
SGLT2 (sodium-glucose co-transporter 2) inhibitors are a class of drugs that have garnered tremendous interest in recent years, particularly for their use in managing type 2 diabetes. They work by inhibiting the reabsorption of glucose in the kidneys, leading to its excretion through urine and thus lowering blood glucose levels. In 2020, estimates suggest around 6 million people were prescribed SGLT2 inhibitors such as Jardiance or Invokana. The usage seems to be on an upward trend due to their additional benefits like weight loss and cardiovascular protection.
On the other hand, SGLT1 (sodium-glucose co-transporter 1) is primarily found in the intestines where it aids carbohydrate absorption into systemic circulation. To date, there have been fewer therapeutic developments targeting SGLT1 compared to SGLT2 because complete inhibition of this transporter could lead to gastrointestinal side effects from unabsorbed carbohydrates. However, research is ongoing with regards to dual SGLT1/SGLT2 inhibitors which might offer superior glycemic control while minimizing potential side effects.
Conclusion
SGLT2 (sodium-glucose co-transporter 2) and SGLT1 (sodium-glucose co-transporter 1) inhibitors are both classes of medications used to manage type 2 diabetes. They work by blocking the reabsorption of glucose in the kidneys, hence reducing blood sugar levels. Both have been shown to be effective treatments for managing type 2 diabetes in numerous clinical trials.
The application of these two types of inhibitors differs due to their location and function within the body. SGLT2, which accounts for about 90% of renal glucose reabsorption, is primarily found in kidney cells; therefore, drugs that inhibit it prevent a significant amount of glucose from being absorbed back into the bloodstream. Examples include dapagliflozin and canagliflozin.
On the other hand, SGLT1 plays a crucial role in intestinal glucose absorption as well as some renal reabsorption – this means drugs targeting it not only impact kidney function but also reduce post-meal spikes in blood sugar by slowing down carbohydrate absorption from gut.
Both drug classes can cause side effects such as urinary tract infections because they increase sugar excretion via urine. However, SGLT2 inhibitors have a higher risk profile than SGLT1 inhibitors due to potential risks like diabetic ketoacidosis or bone fractures.
As with any medication regimen, patients need careful monitoring when starting treatment with either type of inhibitor - regular check-ups will help detect potential complications early on.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Ni, L., Yuan, C., Chen, G., Zhang, C., & Wu, X. (2020, June 26). SGLT2i: beyond the glucose-lowering effect. Cardiovascular Diabetology. Springer Science and Business Media LLC.http://doi.org/10.1186/s12933-020-01071-y
- Jabbour, S. A., Whaley, J. M., Tirmenstein, M., Poucher, S. M., Reilly, T. P., Boulton, D. W., … Parikh, S. (2012, July). Targeting Renal Glucose Reabsorption for the Treatment of Type 2 Diabetes Mellitus Using the SGLT2 Inhibitor Dapagliflozin. Postgraduate Medicine. Informa UK Limited.http://doi.org/10.3810/pgm.2012.07.2569
- Lehmann, A., & Hornby, P. J. (2016, June 1). Intestinal SGLT1 in metabolic health and disease. American Journal of Physiology-Gastrointestinal and Liver Physiology. American Physiological Society.http://doi.org/10.1152/ajpgi.00068.2016
- Tsimihodimos, V., Filippas-Ntekouan, S., & Elisaf, M. (2018, November). SGLT1 inhibition: Pros and cons. European Journal of Pharmacology. Elsevier BV.http://doi.org/10.1016/j.ejphar.2018.09.019
- Peters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015, June 15). Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition. Diabetes Care. American Diabetes Association.http://doi.org/10.2337/dc15-0843
- Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2013, October). SGLT inhibitors in management of diabetes. The Lancet Diabetes & Endocrinology. Elsevier BV.http://doi.org/10.1016/s2213-8587(13)70050-0
- Ghosh, R. K., Bandyopadhyay, D., Hajra, A., Biswas, M., & Gupta, A. (2016, June). Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies. International Journal of Cardiology. Elsevier BV.http://doi.org/10.1016/j.ijcard.2016.02.134
- Lam, K. S. L., Chow, C. C., Tan, K. C. B., Ma, R. C. W., Kong, A. P. S., Tong, P. C. Y., … Tomlinson, B. (2016, April 4). Practical considerations for the use of sodium–glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes. Current Medical Research and Opinion. Informa Healthcare.http://doi.org/10.1185/03007995.2016.1161608
- Singh, M., & Kumar, A. (2018, June 12). Risks Associated with SGLT2 Inhibitors: An Overview. Current Drug Safety. Bentham Science Publishers Ltd.http://doi.org/10.2174/1574886313666180226103408
- Hopf, M., Kloos, C., Wolf, G., Müller, U. A., & Müller, N. (2021, February 3). Effectiveness and Safety of SGLT2 Inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2. Journal of Clinical Medicine. MDPI AG.http://doi.org/10.3390/jcm10040571
- Vider, E., Sapir, R., Mosseri, E., & Gavioli, E. (2022, March). Current Perspectives of the Use of Sodium–Glucose Transport-2 Inhibitors for Patients With Heart Failure and Chronic Kidney Disease. Journal of Cardiovascular Pharmacology. Ovid Technologies (Wolters Kluwer Health).http://doi.org/10.1097/fjc.0000000000001176